User login
Key clinical point: Adjuvant treatment with paclitaxel and trastuzumab demonstrated very good long-term survival outcomes in patients with small, node-negative, human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).
Major finding: After a median follow-up of 10.8 years, only 31 invasive disease-free survival events occurred, of which six were locoregional ipsilateral recurrences, nine were new contralateral breast cancers, six were distant recurrences, and 10 were all-cause deaths. The 10-year invasive disease-free survival rate was >90% (91.3%; 95% CI 88.3%-94.4%).
Study details: Findings are from the phase 2 APT study including 406 patients with small (≤3 cm), node-negative, HER2+ BC who received adjuvant paclitaxel+trastuzumab for 12 weeks followed by trastuzumab for 40 weeks to complete a full year of trastuzumab treatment.
Disclosures: This study was funded by Genentech. The authors declared receiving consulting or advisory board fees, grant support, payment, or having other ties with several sources.
Source: Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273-285 (Feb 27). Doi: 10.1016/S1470-2045(23)00051-7
Key clinical point: Adjuvant treatment with paclitaxel and trastuzumab demonstrated very good long-term survival outcomes in patients with small, node-negative, human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).
Major finding: After a median follow-up of 10.8 years, only 31 invasive disease-free survival events occurred, of which six were locoregional ipsilateral recurrences, nine were new contralateral breast cancers, six were distant recurrences, and 10 were all-cause deaths. The 10-year invasive disease-free survival rate was >90% (91.3%; 95% CI 88.3%-94.4%).
Study details: Findings are from the phase 2 APT study including 406 patients with small (≤3 cm), node-negative, HER2+ BC who received adjuvant paclitaxel+trastuzumab for 12 weeks followed by trastuzumab for 40 weeks to complete a full year of trastuzumab treatment.
Disclosures: This study was funded by Genentech. The authors declared receiving consulting or advisory board fees, grant support, payment, or having other ties with several sources.
Source: Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273-285 (Feb 27). Doi: 10.1016/S1470-2045(23)00051-7
Key clinical point: Adjuvant treatment with paclitaxel and trastuzumab demonstrated very good long-term survival outcomes in patients with small, node-negative, human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).
Major finding: After a median follow-up of 10.8 years, only 31 invasive disease-free survival events occurred, of which six were locoregional ipsilateral recurrences, nine were new contralateral breast cancers, six were distant recurrences, and 10 were all-cause deaths. The 10-year invasive disease-free survival rate was >90% (91.3%; 95% CI 88.3%-94.4%).
Study details: Findings are from the phase 2 APT study including 406 patients with small (≤3 cm), node-negative, HER2+ BC who received adjuvant paclitaxel+trastuzumab for 12 weeks followed by trastuzumab for 40 weeks to complete a full year of trastuzumab treatment.
Disclosures: This study was funded by Genentech. The authors declared receiving consulting or advisory board fees, grant support, payment, or having other ties with several sources.
Source: Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273-285 (Feb 27). Doi: 10.1016/S1470-2045(23)00051-7